Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Sees Significant Growth in Short Interest

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) was the recipient of a significant increase in short interest during the month of December. As of December 31st, there was short interest totalling 109,200 shares, an increase of 30.5% from the December 15th total of 83,700 shares. Currently, 0.7% of the company’s stock are short sold. Based on an average daily volume of 625,300 shares, the days-to-cover ratio is presently 0.2 days.

Institutional Investors Weigh In On Sensei Biotherapeutics

An institutional investor recently raised its position in Sensei Biotherapeutics stock. National Bank of Canada FI raised its position in shares of Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 355.8% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 45,575 shares of the company’s stock after acquiring an additional 35,575 shares during the quarter. National Bank of Canada FI owned approximately 0.18% of Sensei Biotherapeutics worth $27,000 at the end of the most recent quarter. 10.50% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $4.00 target price on shares of Sensei Biotherapeutics in a report on Wednesday, January 8th.

Sensei Biotherapeutics Stock Performance

NASDAQ:SNSE traded up $0.02 during mid-day trading on Friday, reaching $0.53. The stock had a trading volume of 947,492 shares, compared to its average volume of 659,269. Sensei Biotherapeutics has a one year low of $0.38 and a one year high of $1.94. The firm has a 50 day moving average price of $0.50 and a two-hundred day moving average price of $0.55. The stock has a market capitalization of $13.33 million, a P/E ratio of -0.45 and a beta of 0.17.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc, an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment.